Lenvatinib, una nueva primera línea en carcinoma hepatocelular: estudio REFLECT

REFLECT TRIAL: Efficacy Results by Investigator and

Independent Imaging Review (IIR) – ORR

CI = confidence interval; mRECIST = modified Response Evaluation Criteria in Solid Tumours; RECIST = Response Evaluation Criteria In Solid Tumours; ORR = objective response rate.

Investigator

assessment (mRECIST)

Independent review

mRECIST

RECIST v1.1

Lenvatinib

Sorafenib

Lenvatinib

Sorafenib

Lenvatinib

Sorafenib

Response rate

ORR

(95% CI)

24.1 %

(20.2, 27.9)

9.2 %

(6.6, 11.8)

40.6 %

(36.2, 45.0)

12.4 %

(9.4, 15.4)

18.8 %

(15.3, 22.3)

6.5 %

(4.3, 8.7)

Odds ratio

(95% CI)

3.13

(2.15, 4.56)

5.01

(3.59, 7.01)

3.34

(2.17, 5.14)

P-value

p<0.00001

1. Lencioni R.

et.al.

Poster presented at the Gastrointestinal Cancers symposium, San Francisco, CA. January 18–20, 2018.